Mid-term clinical outcomes and cardiac function in patients receiving cardiac contractility modulation.
CCM
Cohort study
Devices
Heart failure
Journal
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966
Informations de publication
Date de publication:
29 Aug 2024
29 Aug 2024
Historique:
received:
06
06
2024
accepted:
06
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
aheadofprint
Résumé
To describe the mid-term clinical and functional cardiac contractility modulation therapy (CCM) recipients in an urban population with heart failure. CCM is a non-excitatory electrical therapy for patients with systolic heart failure with NYHA class III symptoms and ejection fraction (EF) 25-45%. How CCM affects a broad range of clinical measures, including diastolic dysfunction (DD) and weight change, is unexplored. We reviewed 31 consecutive patients at our center who underwent CCM implant. NYHA class, hospitalizations, ejection fraction (EF), diastolic function, and weight were compared pre- and post-CCM implant. Mean age and follow-up time was 63 ± 10 years and 1.4 ± 0.8 years, respectively. Mean NYHA class improved by 0.97 functional classes (p < 0.001), and improvement occurred in 68% of patients. Mean annualized hospitalizations improved (0.8 ± 0.8 vs. 0.4 ± 1.0 hospitalizations/year, p = 0.048), and after exclusion of a single outlier, change in annualized days hospitalized also improved (total cohort 3.8 ± 4.7 vs. 3.7 ± 14.8 days/year; p = 0.96; after exclusion, 3.8 ± 4.7 vs. 1.1 ± 1.9 days/year, p < 0.001). Mean EF improved by 8% (p = 0.002), and among those with DD pre-CCM, mean DD improvement was 0.8 "grades" (p < 0.001). Mean weight change was 8.5 pounds lost, amounting to 4% of body weight (p = 0.002, p = 0.002, respectively), with 77% of patients having lost weight after CCM. Five patients (16%) experienced procedural complications; incidence skewed toward early implants. In an observational cohort, CCM therapy resulted in improvement in NYHA class, hospitalizations, systolic and diastolic function, and weight.
Sections du résumé
OBJECTIVES
OBJECTIVE
To describe the mid-term clinical and functional cardiac contractility modulation therapy (CCM) recipients in an urban population with heart failure.
BACKGROUND
BACKGROUND
CCM is a non-excitatory electrical therapy for patients with systolic heart failure with NYHA class III symptoms and ejection fraction (EF) 25-45%. How CCM affects a broad range of clinical measures, including diastolic dysfunction (DD) and weight change, is unexplored.
METHODS
METHODS
We reviewed 31 consecutive patients at our center who underwent CCM implant. NYHA class, hospitalizations, ejection fraction (EF), diastolic function, and weight were compared pre- and post-CCM implant.
RESULTS
RESULTS
Mean age and follow-up time was 63 ± 10 years and 1.4 ± 0.8 years, respectively. Mean NYHA class improved by 0.97 functional classes (p < 0.001), and improvement occurred in 68% of patients. Mean annualized hospitalizations improved (0.8 ± 0.8 vs. 0.4 ± 1.0 hospitalizations/year, p = 0.048), and after exclusion of a single outlier, change in annualized days hospitalized also improved (total cohort 3.8 ± 4.7 vs. 3.7 ± 14.8 days/year; p = 0.96; after exclusion, 3.8 ± 4.7 vs. 1.1 ± 1.9 days/year, p < 0.001). Mean EF improved by 8% (p = 0.002), and among those with DD pre-CCM, mean DD improvement was 0.8 "grades" (p < 0.001). Mean weight change was 8.5 pounds lost, amounting to 4% of body weight (p = 0.002, p = 0.002, respectively), with 77% of patients having lost weight after CCM. Five patients (16%) experienced procedural complications; incidence skewed toward early implants.
CONCLUSION
CONCLUSIONS
In an observational cohort, CCM therapy resulted in improvement in NYHA class, hospitalizations, systolic and diastolic function, and weight.
Identifiants
pubmed: 39210240
doi: 10.1007/s10840-024-01900-0
pii: 10.1007/s10840-024-01900-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Abraham WT, Fonarow GC, Albert NM, et al. OPTIMIZE-HF Investigators and Coordinators. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008;52:347–56.
doi: 10.1016/j.jacc.2008.04.028
pubmed: 18652942
Abraham WT, Kuck KH, Goldsmith RL, et al. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation. J Am Coll Cardiol Heart Fail. 2018;6:874–83.
Abraham WT, Lindenfeld J, Reddy VY, et al. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with moderately reduced left ventricular ejection fraction and a narrow QRS duration: Study rationale and design. J Cardiac Fail. 2015;21:16–23.
doi: 10.1016/j.cardfail.2014.09.011
Anker SD, Borggrefe M, Neuser H, et al. Cardiac contractility modulation improves long-term survival and hospitalizations in heart failure with reduced ejection fraction. Eur J Heart Failure. 2019;21:1103–13.
doi: 10.1002/ejhf.1374
Borggrefe M, Mann DL. Cardiac contractility modulation in 2018. Circulation. 2018;138:2738–40.
doi: 10.1161/CIRCULATIONAHA.118.036460
pubmed: 30565990
Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol. 2005;289:501–12.
doi: 10.1152/ajpheart.00138.2005
Cheng RK, Cox M, Neely ML, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J. 2014;168:721–30.
doi: 10.1016/j.ahj.2014.07.008
pubmed: 25440801
Dini FL, Ballo P, Pugliese NR, et al. Improved diastolic dysfunction is associated with higher forward flow and better prognosis in chronic heart failure. Int J Cardiovasc Imaging. 2022;38:727–37.
doi: 10.1007/s10554-021-02457-z
pubmed: 34727251
Fastner C, Yuecel G, Rudic B, et al. Cardiac contractility modulation in patients with ischemic versus non-ischemic cardiomyopathy: results from the MAINTAINED observational study. Int J Cardiol. 2021;342:49–55.
doi: 10.1016/j.ijcard.2021.07.048
pubmed: 34329680
Feaster TK, Casciola M, Narkar A, et al. Acute effects of cardiac contractility modulation on human induced pluripotent stem cell-derived cardiomyocytes. Physiol Rep. 2021;9:e15085.
doi: 10.14814/phy2.15085
pubmed: 34729935
pmcid: 8564440
Gorodeski EZ, Magnelli-Reyes C, Moennich LA, et al. Cardiac resynchronization therapy-heart failure (CRT-HF) clinic: a novel model of care. PLoS ONE. 2019;14:e0222610.
doi: 10.1371/journal.pone.0222610
pubmed: 31536565
pmcid: 6752801
Guha A, Maddox WR, Colombo R, et al. Cardiac implantable electronic device infection in patients with end-stage renal disease. Heart Rhythm. 2015;12:2395–401.
doi: 10.1016/j.hrthm.2015.08.003
pubmed: 26253036
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145:e895–1032.
pubmed: 35363499
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 American College of Cardiology/American Heart Association/Heart Failure Society of America guideline for the management of heart failure: executive summary. J Card Fail. 2022;28:810–30.
doi: 10.1016/j.cardfail.2022.02.009
pubmed: 35378259
Juenger J, Schellberg D, Kraemer S, et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart. 2002;87:235–41.
doi: 10.1136/heart.87.3.235
pubmed: 11847161
pmcid: 1767036
Kadish A, Nademanee K, Volosin K, et al. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am Heart J. 2011;161:329–37.
doi: 10.1016/j.ahj.2010.10.025
pubmed: 21315216
Ko DT, Alter DA, Austin PC, et al. Life expectancy after an index hospitalization for patients with heart failure: a population-based study. Am Heart J. 2008;155:324–31.
doi: 10.1016/j.ahj.2007.08.036
pubmed: 18215604
Kuschyk J, Falk P, Demming T, et al. Long-term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system. Eur J Heart Fail. 2021;23:1160–9.
doi: 10.1002/ejhf.2202
pubmed: 34002440
Lawo T, Borggrefe M, Butter C, et al. Electrical signals applied during the absolute refractory period: an investigational treatment for advanced heart failure in patients with normal QRS duration. J Am Coll Cardiol. 2005;46:2229–36.
doi: 10.1016/j.jacc.2005.05.093
pubmed: 16360051
Leyva F, Zegard A, Patel P, et al. Improved prognosis after cardiac resynchronization therapy over a decade. Europace. 2023;25:1–11.
doi: 10.1093/europace/euad141
Linde C, Grabowski M, Ponikowski P, et al. Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM-HFpEF). Eur J Heart Fail. 2022;24:2275–84.
doi: 10.1002/ejhf.2619
pubmed: 35855646
Loccoh EC, Joynt Maddox KE, Wang Y, Kazi DS, Yeh RW, Wadhera RK. Rrural-urban disparities in outcomes of myocardial infarction, heart failure, and stroke in the United States. J Am Coll Cardiol. 2022;79:267–79.
doi: 10.1016/j.jacc.2021.10.045
pubmed: 35057913
pmcid: 8958031
Madhavan M, Waks JW, Friedman PA, et al. Outcomes after implantable cardioverter-defibrillator generator replacement for primary prevention of sudden cardiac death. Circ Arrhythm Electrophysiol. 2016;9:e003283.
doi: 10.1161/CIRCEP.115.003283
pubmed: 26921377
pmcid: 4998185
McDermott KW, Roemer M. Most frequent principal diagnoses for inpatient stays in U.S. Hospitals, 2018. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs 2021; 277.
McDowell K, Petrie MC, Raihan NA, et al. Effects of intentional weight loss in patients with obesity and heart failure: a systematic review. Obes Rev. 2018;19:1189–204.
doi: 10.1111/obr.12707
pubmed: 30051959
Mentias A, Desai MY, Vaughan-Sarrazin MS, et al. Community-level economic distress, race, and risk of adverse outcomes after heart failure hospitalization among Medicare beneficiaries. Circulation. 2022;1245:110–21.
doi: 10.1161/CIRCULATIONAHA.121.057756
Mullens W, Grimm RA, Verga T, et al. Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol. 2009;53:765–73.
doi: 10.1016/j.jacc.2008.11.024
pubmed: 19245967
Neelagaru SB, Sanchez JE, Lau SK, et al. Nonexcitatory, cardiac contractility modulation electrical impulses: feasibility study for advanced heart failure in patients with normal QRS duration. Heart Rhythm. 2006;3:1140–7.
doi: 10.1016/j.hrthm.2006.06.031
pubmed: 17018340
Pappone C, Augello G, Rosanio S, et al. First human chronic experience with cardiac contractility modulation by nonexcitatory electrical currents for treating systolic heart failure: mid-term safety and efficacy results from a multi-center study. J Cardiovasc Electrophysiol. 2004;15:418–27.
doi: 10.1046/j.1540-8167.2004.03580.x
pubmed: 15089990
Podmolik ME. Modern healthcare. Available at: https://www.modernhealthcare.com/databases . Accessed February 26, 2024.
Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017;6:187–94.
doi: 10.1007/s13679-017-0262-y
pubmed: 28455679
pmcid: 5497590
Sherazi S, Shah F, Kutyifa V, et al. Risk of ventricular tachyarrhythmic events in patients who improved beyond guidelines for a defibrillator in MADIT-CRT. J Am Coll Cardiol EP. 2019;10:1172–81.
Springer J, Filippatos G, Akashi YJ, Anker SD. Prognosis and therapy approaches of cardiac cachexia. Curr Opin Cardiol. 2006;21:229–33.
doi: 10.1097/01.hco.0000221585.94490.09
pubmed: 16601462
Yuyun MF, Erqou SA, Peralta AO, et al. Ongoing risk of ventricular arrhythmias and all-cause mortality at implantable cardioverter defibrillator generator change: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2021;14:e009139.
doi: 10.1161/CIRCEP.120.009139
pubmed: 33554611